CHRISTIE BALLANTYNE to Coronary Angiography
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Coronary Angiography.
Connection Strength
0.531
-
Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation. 2008 May 13; 117(19):2458-66.
Score: 0.255
-
Lipoprotein(a) and Progression of Coronary Artery Calcification in a Pooled?U.S. Cohort. JACC Cardiovasc Imaging. 2024 Oct; 17(10):1265-1267.
Score: 0.049
-
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016 12 13; 316(22):2373-2384.
Score: 0.029
-
Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). Am Heart J. 2016 Jun; 176:83-92.
Score: 0.028
-
Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial. Am J Cardiovasc Drugs. 2016 Feb; 16(1):55-65.
Score: 0.027
-
Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players. Atherosclerosis. 2014 Oct; 236(2):251-6.
Score: 0.025
-
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J. 2014 Dec 07; 35(46):3277-86.
Score: 0.024
-
Neck circumference is not associated with subclinical atherosclerosis in retired National Football League players. Clin Cardiol. 2014 Jul; 37(7):402-7.
Score: 0.024
-
ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies. Cardiovasc Drugs Ther. 2012 Apr; 26(2):181-7.
Score: 0.021
-
Delayed recovery of severely "stunned" myocardium with the support of a left ventricular assist device after coronary artery bypass graft surgery. J Am Coll Cardiol. 1987 Sep; 10(3):710-2.
Score: 0.015
-
A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. Atherosclerosis. 2001 Feb 15; 154(3):633-40.
Score: 0.010
-
Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Lipoproteins and Coronary Atherosclerosis Study. Atherosclerosis. 1999 Jun; 144(2):435-42.
Score: 0.009
-
Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol. 1997 Aug 01; 80(3):278-86.
Score: 0.008
-
The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. Control Clin Trials. 1996 Dec; 17(6):550-83.
Score: 0.007